The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in
Sponsorship statement:
This educational masterclass has been solely funded by a grant from BTG Pharmaceuticals (a SERB company). BTG were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by OmniaMed Communications Ltd.
SERB_RGB_700

Masterclass: Digoxin, heart failure and the elderly

27 March 2024
Available for 1 CPD point(s)

Masterclass

Join Professor Chim Lang and Dr Su-Lee Xiao as they discuss the role that digoxin still has to play in heart failure management and what to look out for when treating high-risk patients.
Speakers

Professor Chim Lang Consultant Cardiologist and Clinical Pharmacologist, University of Dundee
Dr Su-Lee Xiao Geriatric Medicine Registrar, London

Learning objectives

  • When to use digoxin and why
  • Digoxin benefits and limitations
  • Identifying digoxin toxicity
  • How to address digoxin toxicity in your heart failure patients
  • How to monitor digoxin levels

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 75%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References
  1. Belz GG et al. Eur J Clin Invest 2001;31(Suppl 2):S10–S17.
  2. Digoxin SmPC. 2022 Available at: https://www.medicines.org.uk/emc/product/5465/smpc#gref (accessed February 2024)
  3. Rehman R, Hai O. Digitalis toxicity. 2023. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459165/ (accessed March 2024)
  4. Ziff OJ, Kotecha D. Trends Cardiovasc Med 2016;26:585–95.
  5. Savarese G et al. JACC Heart Fail 2019;7:306–317.
  6. Wagner L, Kenreigh C. Digoxin. In Enna SJ, Bylund DB (eds). xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc, 2007:1–6.

Categories

Tags

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

  • Paul Foley, Terry McCormack

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

© 2025 Medinews Cardiology Ltd, a wholly-owned subsidiary of OmniaMed Communications Ltd   |   Privacy & cookies policy   |   Terms & conditions

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.